Related Experiment Video

Updated: Oct 10, 2026

Mouse Round Spermatid Injection
08:41

Mouse Round Spermatid Injection

Published on: January 26, 2024

Advanced germ cell tumors in male patients

Z Nahleh1, J Gallardo, I A Tabbara

  • 1Bone Marrow Transplant Program, George Washington University School of Medicine, Washington, DC, USA.

Southern Medical Journal
|November 30, 2000
PubMed

Insights

Treating male germ cell tumors (GCTs) in young patients is crucial. Current chemotherapy is effective, but research explores high-dose options and new agents for better outcomes in poor-risk GCT.

Area of Science:

  • Oncology
  • Urologic Oncology

Background:

  • Male germ cell tumors (GCTs) significantly impact young patients.
  • Poor-risk GCTs have a 50% long-term survival rate.
  • Current standard chemotherapy involves bleomycin, etoposide, and cisplatin.

Purpose of the Study:

  • To review prognostication systems for male GCTs.
  • To highlight research areas for improving treatment outcomes.
  • To discuss future approaches for understanding and managing GCTs.

Main Methods:

  • Review of major prognostication systems.
  • Analysis of ongoing research in GCT treatment.
  • Evaluation of novel chemotherapeutic agents.

Main Results:

  • The combination of bleomycin, etoposide, and cisplatin remains a standard chemotherapy regimen.
  • High-dose chemotherapy with stem cell transplantation is under investigation for intermediate- and poor-risk GCT.
  • Newer agents like gemcitabine and paclitaxel show promise for future regimens.

Conclusions:

  • Improving survival for young male GCT patients is a key oncologic goal.
  • Research is focused on refining prognostication and exploring advanced therapies.
  • Future management will likely incorporate novel agents and innovative treatment strategies.

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Infertility in Males01:23

Infertility in Males

Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
Spermatogenesis01:41

Spermatogenesis

Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male reproductive...
The Y Chromosome Determines Maleness02:19

The Y Chromosome Determines Maleness

The Y chromosome is a sex chromosome found in several vertebrates and mammals, including humans. In addition to 22 pairs of autosomes, the human males have one X chromosome and one Y chromosome. In these organisms, the presence or absence of the Y chromosome determines the development of male traits.
Evolution
Around 300 million years ago, the two sex chromosomes diverged from two identical autosomal chromosomes. Over time, the Y chromosome has lost most of its genes, shrinking in size. Today,...